Magnesium in Ketamine Administration in Treatment-Resistant Depression

Górska, Natalia; Cubała, Wiesław Jerzy; Słupski, Jakub; Wiglusz, Mariusz Stanisław; Gałuszko-Węgielnik, Maria; Kawka, Mateusz; Grzegorzewska, Agata

doi:10.3390/ph14050430

Open AccessArticle

Magnesium in Ketamine Administration in Treatment-Resistant Depression

by

Natalia Górska

,

Wiesław Jerzy Cubała

,

Jakub Słupski

,

Mariusz Stanisław Wiglusz

,

Maria Gałuszko-Węgielnik

,

Mateusz Kawka

^* and

Agata Grzegorzewska

Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, 80-952 Gdańsk, Poland

^*

Author to whom correspondence should be addressed.

Pharmaceuticals 2021, 14(5), 430; https://doi.org/10.3390/ph14050430

Submission received: 18 March 2021 / Revised: 27 April 2021 / Accepted: 30 April 2021 / Published: 3 May 2021

(This article belongs to the Special Issue Psychopharmacology of Affective Disorders)

Download

Browse Figures

Versions Notes

Abstract

Relationship between depression and magnesium levels is reported. This observational study examined whether serum magnesium concentration change over time of ketamine treatment course, also whether association between magnesium concentrations and treatment response measured with Montgomery-Åsberg Depression Rating Scale (MADRS) score occurs. Moreover, interlink between changes in Young Mania Rating Scale (YMRS) score, somatic comorbidities, and magnesium concentration was studied. Inpatients with major depressive disorder or bipolar disorder were rated weekly by clinician using MADRS and YMRS. Magnesium levels assessments were carried out weekly, before start of ketamine treatment and then every second infusion and one week after last ketamine infusion. The concentration of Mg²⁺ ions differs depending on the measurement. The Mg²⁺ concentration in pre-measurement was significantly higher than in measurement after five infusions (p = 0.031) and after seven infusions (p = 0.003). No significant correlation was observed between changes in magnesium serum levels and MADRS or YMRS. The concentration of Mg²⁺ ion in course of the treatment was not associated with somatic comorbidities. The study supports data for role of magnesium in treatment-resistant depression, particularly related to ketamine treatment, but provides no clear evidence of straightforward association between magnesium serum concentration and treatment response or comorbidity.

Keywords: magnesium; ketamine; treatment-resistant depression

Share and Cite

MDPI and ACS Style

Górska, N.; Cubała, W.J.; Słupski, J.; Wiglusz, M.S.; Gałuszko-Węgielnik, M.; Kawka, M.; Grzegorzewska, A. Magnesium in Ketamine Administration in Treatment-Resistant Depression. Pharmaceuticals 2021, 14, 430. https://doi.org/10.3390/ph14050430

AMA Style

Górska N, Cubała WJ, Słupski J, Wiglusz MS, Gałuszko-Węgielnik M, Kawka M, Grzegorzewska A. Magnesium in Ketamine Administration in Treatment-Resistant Depression. Pharmaceuticals. 2021; 14(5):430. https://doi.org/10.3390/ph14050430

Chicago/Turabian Style

Górska, Natalia, Wiesław Jerzy Cubała, Jakub Słupski, Mariusz Stanisław Wiglusz, Maria Gałuszko-Węgielnik, Mateusz Kawka, and Agata Grzegorzewska. 2021. "Magnesium in Ketamine Administration in Treatment-Resistant Depression" Pharmaceuticals 14, no. 5: 430. https://doi.org/10.3390/ph14050430

APA Style

Górska, N., Cubała, W. J., Słupski, J., Wiglusz, M. S., Gałuszko-Węgielnik, M., Kawka, M., & Grzegorzewska, A. (2021). Magnesium in Ketamine Administration in Treatment-Resistant Depression. Pharmaceuticals, 14(5), 430. https://doi.org/10.3390/ph14050430

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Magnesium in Ketamine Administration in Treatment-Resistant Depression

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI